| 原发性肝癌临床分期的对比探讨.原发性肝癌临床分期的对比探讨[J].,2014,14(8):1576-1579 |
| 原发性肝癌临床分期的对比探讨 |
| The Comparison and Discussion on the Clinical Staging Systems of PrimaryLiver Cancer |
| |
| DOI： |
| 中文关键词: 原发性肝癌 临床分期 预后 对比 |
| 英文关键词: Primary liver cancer Staging systems Prognosis Comparison |
| 基金项目: |
|
| 摘要点击次数: 889 |
| 全文下载次数: 1534 |
| 中文摘要: |
| 摘要：原发性肝癌严重威胁着人类的健康，全球每年新增的病例数约为50 万，其中54%发生在我国，且患者在3 年内复发率高于
60%，可见诊治形势十分严峻。肝癌的临床分期系统对于患者的预后评估以及选择何种治疗方案有着极其重要的意义。国内外虽
有此类研究的相关内容，但将各种分期的评价及适用范围、发展趋势相结合进行分析的较少。本文对国际上多种常用的分期方案
（TNM 分期、Child-Pugh 分期、Okuda 分期、CLIP 评分、JIS 分期、CUPI指标、CIS记分）进行探讨，论述各种方案间的差异及相互关
系，并对未来可能发展方向进行展望。经本文分析多项研究发现：TNM分期更适用于外科病人，Child-Pugh 对肝功能受损的患者
具有较好的预后价值，而Okuda、CLIP、JIS 分期适用于不适合手术治疗的进展期病人，CUPI指数则对慢性乙肝患者有疗效，CIS
适用于非手术治疗的患者。随着肿瘤分子生物学技术的进步，肝癌分期有可能上升到分子病理学的水平，肝癌切除的根治程度将
划分得更为细致，以反映患者肝癌切除后所处状态的多种可能性，分子指标也将更加客观、敏感，有利于患者早期的诊断与治疗。 |
| 英文摘要: |
| ABSTRACT:Primary liver cancer threatens people's health severely. Over five hundred thousand new cases are diagnosed each
year on worldwide. A total of 54%of these patients were diagnosed in china, and recurrence rates of those patients are higher than 60%.
Thus, the treatment situation of primary liver cancer is very serious. Clinical staging systems are very significant to evaluate prognosis,
and make clinical treatment plan on primary liver cancer patients. Some related studies have been discussed in the world, but it is few of
integration on evaluation, application and prospect for development. Several common clinical staging systems are compared and discussed,
including TNM system, Child-Pugh, Okuda staging system and CLIP, JIS, CUPI, CIS system. Multiple studies have shown that:
TNM is suitable for surgical patients; Child-Pugh system has better prognosis value on patients with liver function damage. Staging systems
of Okuda, CLIP and JIS are not good for patients on hospitalized and underwent operation. Hepatitis B patients are suitable for using
CUPI index, CIS score are better on no-surgical patients. With the developmental technology of tumor molecular biological, primary
liver cancer staging systems could evolvement upon molecular pathology. The level of primary liver cancer radical resection will be more
in detail, in order to reflect multiple possibilities of patients status on radical resection. With the development of objective and sensitive
molecular index, diagnosis and treatment will be more prompt. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
